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Abstract 
Allergic diseases often occur early in life and persist throughout life. This life‑course perspective should be considered 
in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old 
age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways 
diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy 
ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immu‑
notherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age 
adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunother‑
apy, its mechanisms and the concept of active and healthy ageing.
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Background
Allergic diseases often occur early in life and persist 
throughout life. This life-course perspective should 
be considered in allergen immunotherapy (AIT). In 
particular it is essential to understand whether this 
immunological treatment may be used in old age adults.
The current paper was developed by a working group 
of AIRWAYS integrated care pathways (ICPs for airways 
diseases), the model of chronic respiratory diseases of the 
European Innovation Partnership on active and healthy 
ageing (DG CONNECT and DG Santé) to develop the 
concept of AIT across the life cycle and propose a strate-
gic framework to be tested.
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AIRWAYS integrated care pathways
The political background
Active and healthy ageing (AHA) is a major societal chal-
lenge, common to all populations. Ageing, together with 
gender, socio-economic and other forms of inequalities 
(https://www.equalityhumanrights.com/en/equality-act/
protected-characteristics), is an under-appreciated cause 
of poor health, which can have an adverse impact on eco-
nomic development [1]. To tackle the burden of ageing 
in the European Union (EU), the European Commission 
launched the European Innovation Partnership (EIP) on 
AHA within its innovation policy [2]. The EIP on AHA is 
proposing a novel approach [2] that may be of great ben-
efit to the economic consequences of the demographic 
changes in Poland. EIPs aim to enhance EU competi-
tiveness and tackle societal challenges through research 
and innovation. They will address weaknesses in the EU 
research and innovation (e.g. under-investment, frag-
mentation and duplication), which complicate the dis-
covery or exploitation of knowledge and may ultimately 
prevent the entry of innovations into the market place. 
EIP on AHA pursues a triple win for Europe:
  • To enable EU citizens to lead healthy, active and 
independent lives while ageing.
  • To improve the sustainability and efficiency of social 
and health care systems.
  • To boost and improve the competitiveness of the 
markets for innovative products and services, 
responding to the ageing challenge at both EU and 
global level, thus creating new opportunities for busi-
nesses.
ICPs for chronic respiratory diseases (AIRWAYS ICPs) 
have been selected as a model for Action Plan B3 of the 
EIP on AHA Strategic Implementation Plan [3, 4]. The 
goals of AIRWAYS ICPs are to launch a collaboration to 
develop multi-sectoral care pathways for chronic respira-
tory diseases in European countries, regions and beyond 
in association with the World Health Organization 
(WHO) Global Alliance against chronic Respiratory Dis-
eases (GARD research demonstration project) [5]. There 
are several ongoing actions among which:
  • A synergy paper in press.
  • A twinning for rhinitis in the elderly accepted yester-
day by the EU.
  • An App and a tablet for rhinitis and asthma deployed 
in 20 countries which received funding from private 
sources and the EU Development and Structural 
Funds [6–10].
  • The scaling up strategy [11].
Prenatal and early-life events play a fundamental role 
in health and on the development of non-communicable 
diseases (NCDs) and AHA [12]. The Polish Presidency of 
the EU Council targeted chronic respiratory diseases in 
children to promote AHA [13]. It has been recognized 
that the prevention and early diagnosis and treatment 
of chronic respiratory diseases have a positive impact on 
child development and health-related quality of life and 
markedly contribute to an active and healthy childhood 
as well as AHA. Therefore, the development of new tools 
has been proposed for the early recognition and improve-
ment of treatment for these conditions.
Respiratory allergies across the life cycle
IgE-mediated allergic diseases were defined by the World 
Allergy Organization [14] and include allergic rhinitis 
[15], allergic asthma [16], atopic dermatitis (AD) [17] and 
food allergy. However, IgE-mediated allergy is not always 
involved in the symptoms of these diseases [18–21] 
including non-allergic rhinitis, and non-allergic asthma.
Respiratory allergic diseases (asthma and rhinoconjunc-
tivitis) are amongst the most common diseases worldwide 
[16]. They affect all age groups and rank first in Europe. 
The burden of these allergic diseases is substantial [22, 
23] since they often impair social life as well as school 
and work performances [15, 24, 25]. Many patients are 
untreated or uncontrolled (despite treatment) [26], remain 
under-diagnosed and often do not receive adequate treat-
ment. These factors all contribute to poor disease control.
Allergic diseases often start early in life and tend to 
persist across the life cycle, from infancy to the elderly. 
This is especially true with asthma or rhinitis, which may 
cause problems in individuals over 65  years of age [27]. 
Longitudinal birth cohort studies have shown sequential 
events leading to upper and lower respiratory allergies 
[28, 29]. They start with weak sensitizations to a limited 
number of allergen components followed by strong and/
or new sensitizations to varying allergen sources depend-
ing on the region of the world [30–34]. However, in a 
large number of patients, sensitization does not change 
over time and is fully developed in pre-school children 
[29, 32, 35]. Moreover, the allergic march is uncommon 
[36]. The escalation of sensitization parallels with the 
clinical expression of the allergic disease. Genuine sensi-
tizers (either for food- or inhalant-related allergens) tend 
to appear early in life, whereas specific IgE to pan-aller-
gens appear later [37].
Cohort studies following participants into middle age 
have indicated that several factors, including childhood 
asthma, low or impaired lung function at an early age 
as well as atopy are risk factors for chronic obstructive 
pulmonary disease (COPD) [38, 39]. In asthma, allergic 
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sensitization was associated with worsening of health-
related quality of life [40] in the elderly, with a high mor-
tality risk due to under-diagnosis, under-treatment and 
comorbidity [41]. First-time exposure to an occupational 
allergen in any context (e.g. during apprenticeship) is 
indeed a period of increased risk of developing work-
related respiratory allergic diseases such as asthma and 
allergic rhinitis [42]. For example, occupational cleaners 
are associated with an increased risk of developing both 
asthma and self-reported COPD [43]. Established occu-
pational asthma may persist in spite of complete allergen 
avoidance.
Over the past five decades, an “epidemic” of aller-
gic diseases and asthma has been observed globally in 
children and adults [5]. The expected epidemic wave of 
asthma and rhinitis in elderly adults remains an insuffi-
ciently recognized problem [44–46]. In Europe, over 20% 
of adults suffer from allergic rhinitis and over 5% from 
asthma [15, 47]. These patients are now reaching the age 
of 65 and a new health challenge in elderly people will be 
to understand, detect and manage them. The importance 
of AIT in these patients needs to be better defined, tested 
and included in health policy making for the elderly [13].
Since we are entering an era of rapidly increasing 
elderly people, and considering that asthma and rhinitis 
usually commence during childhood or adulthood, both 
diseases represent an emerging public health concern in 
all age populations [48, 49].
Rationale of allergy immunotherapy across the life 
cycle in AIRWAYS ICPs
Allergy and allergen immunotherapy scope
Immunotherapy for IgE-mediated allergic diseases, 
referred to as AIT, has entered a new era [50–53]. It is 
characterized by: (1) thorough clinical development pro-
grammes leading to full registration and standardization 
of products; (2) better understanding of the functions 
of the immune system; (3) development of new prod-
ucts and routes to improve efficacy and safety; and (4) 
harmonized clinical practice parameters based on both 
evidence-based medicine and clinical experience. AIT 
includes both allergen- and non-allergen-containing 
therapeutics and is fully supported by the Polish Presi-
dency of the Council of the EU [13] and the Finnish 
Allergy Plan [27, 54]. Although dosing is now established 
for some major allergens [55, 56], mixing of allergens is 
still a matter of debate and the selection of the allergen in 
some polysensitized patients may still be difficult.
AIT induces immune tolerance
The goals for AIT are to control the symptoms of patients 
who are unable to cope with their disease using optimal 
pharmacotherapy [9, 57, 58]. Ultimately, AIT aims to 
induce immune tolerance so that after its discontinua-
tion, there are persistent therapeutic benefits [59, 60]. 
Whereas the early effects of AIT are probably related to 
basophil/mast cell down-regulation, AIT produces an 
early and transient inflammatory cell down-regulation 
and a transient to long-lasting T cell tolerance [61, 62]. 
This “tolerance” response is mainly mediated by IL-10, 
TGF-β and other suppressive factors causing immune 
deviation towards a more balanced T regulatory cell 
response that leads to the observed suppression of 
cytokines from allergen-specific Th1 and Th2 cells [26, 
63]. AIT also induces allergen-specific IL-10-producing 
memory B regulatory cells, which seem to be responsible 
for specific IgG4 production. Furthermore, AIT is asso-
ciated with the suppression of total IgE, allergen-specific 
IgE, increases in allergen-specific blocking IgG4 anti-
bodies [64, 65], a decrease in both tissue mast cells and 
eosinophil numbers [66] and the degree of activation.
AIT efficacy and safety
Clinical efficacy and safety of AIT for allergic asthma and 
allergic rhinoconjunctivitis for the most relevant allergen 
sources have been documented in well-powered rand-
omized controlled trials, at least for specific products. 
Different systematic reviews and meta-analyses of stud-
ies in adults and children have confirmed efficacy for 
many relevant allergen sources [67–71]. However, some 
reviews were critical about AIT although certain criti-
cisms were raised [72]. AIT improves disease-specific 
quality of life [73, 74]. Follow-up studies after the discon-
tinuation of AIT have demonstrated a carry-over effect 
which can last for up to 12 years after its cessation [69, 
75], but these studies are hampered by a high rate of drop 
outs and the effectiveness of these long-lasting effects 
needs more attention. AIT is thus a disease-modifying 
intervention (the only one currently available) with the 
potential of altering the allergic march [76, 77]. Double 
blind randomized controlled studies are currently ongo-
ing in children allergic to grass pollens [78] and house 
dust mite to assess the potential prevention of asthma 
(EudraCT 2012-005678-76) (Table  1). It has been sug-
gested that AIT is cost-effective although more informa-
tion is needed [53, 79, 80].
Unmet needs
 1. Tolerance to AIT in very young children Considering 
that children born to atopic parents are at consider-
able increased risk of sensitization to common envi-
ronmental allergens [81], it is important to establish 
the possible preventive role of AIT in reducing sen-
sitization (primary prevention) to any allergens when 
given at infancy although the first results are incon-
clusive [82, 83] or difficult to interpret [84].
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 2. When to start AIT in preschool children The dem-
onstration of a progressive molecular-spreading 
process in allergic rhinitis [30] has provided the 
rationale for an early allergen-specific immunologi-
cal intervention [85]. In this respect, studies on a 
‘secondary allergen immuno-prophylaxis’ may be 
targeted to children who are already sensitized to 
airborne allergens but still asymptomatic. The on-
going allergic immune response is likely to be more 
susceptible of being suppressed in the first, weaker, 
pre-clinical monomolecular stages, rather than in 
the polymolecular clinical stages. It is also plausible 
that AIT will have a greater efficacy if started imme-
diately after the disease onset rather than, as usual, 
years later. This concept of ‘early AIT’ should be 
tested in properly designed prospective trials [85].
  The results of the EU programme on Mechanisms 
of the Development of ALLergy (MeDALL) have 
improved the stratification of allergic preschool 
children for diagnosis, prognosis and AIT [28, 29]. 
Multi-morbidity, co-existing allergic diseases (such 
as atopic eczema, allergic rhinitis and asthma) [86] 
and/or IgE polysensitisation are markers of clinical 
disease and disease persistence. For the first time 
ever, MeDALL is proposing a scientific answer for 
the initiation of AIT in pre-school children as it has 
found that the vast majority of those with multi-
morbidities will have persistent allergic conditions 
[33, 87]. This finding has the potential to guide physi-
cians to consider starting AIT early in life and this 
might lead to a greater expected efficacy to modify 
the course of allergy. Moreover, allergy with poly-
sensitisation to birch pollen [32], cat or dog [31], 
or peanut (Asarnoj, in preparation) at age four can 
predict the onset and/or persistence of rhinitis and 
asthma at 16 years. The MeDALL results have been 
confirmed in patient cohorts [88, 89]. It is therefore 
suggested that preschool children with asthma and 
rhinitis already sensitized may be considered as can-
didates for AIT.
 3. Clinical tools to evaluate AIT There is a high degree 
of clinical and methodological heterogeneity among 
the endpoints in clinical studies on AIT, for both 
SCIT (sub-cutaleous AIT) and SLIT (sublingual 
AIT). At present, there are no commonly accepted 
standards for defining the optimal outcome parame-
ters to be used for both primary and secondary end-
points [90]. A Task Force of the European Academy 
of Allergy and Clinical Immunology (EAACI) Immu-
notherapy Interest Group evaluated the currently 
used outcome parameters in different RCTs and pro-
vided recommendations for the optimal endpoints in 
future AIT trials for allergic rhinoconjunctivitis. Rec-
ommendations for nine domains of clinical outcome 
measures were made and recommended a homo-
geneous combined symptom and medication score 
(CSMS) was recommended as a primary outcome 
[90]. New ICT-based technology is likely to consid-
erably change patient reported outcomes (PROs) for 
AIT during clinical trials and daily practice [6, 7, 91].
  PROs should be adapted to the age groups. Caregiv-
ers are less able than children to accurately assess 
response to treatment with available tools. A simple 
pediatric-specific tool to assess efficacy in allergic 
rhinitis trials in children is needed [92–95]. In older 
adults, very few studies have investigated PROs, but 
visual analogue scales appear to be of interest [92, 96, 
97].
 4. Stratification of patients allowing precision medi-
cine Precision medicine is a medical model aim-
ing to deliver customized healthcare—with medical 
decisions, practices, and/or products tailored to the 
individual patient. AIT has a unique immunological 
rationale, since the approach is tailored to the spe-
cific IgE sensitization of an individual. It modifies the 
natural course of the disease as it aims to have a per-
sistent efficacy after completion of treatment. In this 
perspective, AIT can be considered a prototype of 
precision medicine [98]. Biomarkers associated with 
e-health, combined with a clinical decision support 
system (CDSS), might change the scope of AIT.
 5. Relevant immune mechanisms Several immune 
changes have been associated with AIT. However, 
the most relevant immune mechanisms leading 
to clinical successful AIT have not yet been identi-
fied. This might be due to different administrations 
of AIT, different allergens, different products, etc. 
Deciphering the relevant immune mechanisms is 
of the upmost importance to further improve treat-
ment protocols, finding relevant biomarkers, and to 
improve the composition of AIT products.
 6. Biomarkers Biomarkers in allergic diseases and 
asthma are of great importance and a large body of 
Table 1 Types of biomarkers for AIT
Identification and validation of biomarkers assessing the probability of 
response to treatment of AIT before it is initiated
Identification and validation of biomarkers assessing the safety of AIT 
before it is initiated
Identification and validation of biomarkers confirming the efficacy of AIT 
in patients receiving AIT (short and long term)
Identification and validation of biomarkers predicting the long‑term 
effects of AIT before it is stopped
Identification and validation of biomarkers predicting the relapse of 
symptoms when AIT is stopped
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research has been initiated [98]. The identification of 
biomarkers is based on systems biology approaches 
combining transcriptomics, proteomics, epigenetics 
and metabolomics in large patient cohorts. Two EU-
funded projects are currently ongoing: U-BIOPRED 
(IMI) in severe asthma [99–101] and MeDALL 
(FP7) in allergy [28, 29]. These projects will help to 
identify biomarkers for AIT efficacy [102–104] and 
safety, and to better establish the personalized medi-
cine approach [105]. The following issues should be 
addressed (Table 1):
 7. IgE sensitization profiles Combinatorial analysis has 
shown that the IgE sensitization profiles to grass pol-
len in children with hay fever are very heterogene-
ous at the molecular level [34, 106, 107]. This high 
heterogeneity is important in a scenario of preci-
sion medicine. Accordingly, a classification of dif-
ferent categories of match and mismatch between 
the molecular profiles of IgE sensitization and the 
molecular profile of an AIT preparation has been 
illustrated [106]. Studies are needed to evaluate 
the putative impact of matched or mismatched IgE 
between the sensitization profile and the molecu-
lar composition of the AIT preparation used in the 
individual patient. Moreover, recent studies in over 
1300 Italian children with seasonal allergic rhinitis 
have shown the importance of component-resolved 
diagnosis (CRD) on the prescription of AIT against 
pollens [108]. Molecular diagnosis with marker 
allergens is nowadays a promising diagnostic step in 
poly-sensitized individuals and it is essential to dis-
tinguish the primary sensitizers and “true” reactions 
from cross-reactivity caused by pan-allergens.
  AIT efficacy may be predicted by the IgE profile 
[102, 109, 110], but more data are needed.
 8. AIT in older adults The role of AIT for the treatment 
of allergic diseases in old age should be considered. 
The research agenda must include not only well pow-
ered randomized controlled trials in this age group 
but also specific research on the immune response, 
time of onset of allergic disease (since childhood, 
adult life or late-onset in life), comorbidities, safety 
and cost-benefits of AIT.
 9. AIT in pregnancy Allergic diseases such as asthma 
and allergic rhinitis constitute a significant burden 
among women of childbearing age and those who 
are pregnant. The continuation of AIT during preg-
nancy appears safe [111]. Available studies do not 
however show a convincing reduction in the devel-
opment of atopy in offspring from the administration 
of AIT during pregnancy [111].
 10. AIT for skin allergy A Cochrane review found limited 
evidence that AIT may be effective for people with 
atopic eczema [112]. The treatments used in these 
trials were not associated with an increased risk of 
local or systemic reactions. Future studies should 
use high quality allergen formulations with a proven 
track record in other allergic conditions and should 
include PROs as key outcome measures.
 11. SCIT versus SLIT Direct head-to-head compari-
sons of subcutaneous AIT (SCIT) versus sublingual 
AIT (SLIT; tablets or drops) are limited [113] and 
have generated contradictory results [114]. Simi-
larly, indirect comparisons are inconsistent. This is 
perhaps due to the lack of standardization of clini-
cal outcomes measured, dosages, heterogeneous 
compositions, schedules and duration of treatment 
[67]. There are very few SCIT studies that meet the 
CONSORT criteria for publication and most are 
not ITT analyses [115, 116]. Moreover, efficacy and 
safety have been shown only for some SLIT and 
SCIT products. Comparisons should also be made 
between products [117]. For some allergen sources 
and age groups, effective SLIT or SCIT doses have 
not been established [69].
 12. AIT in polysensitized individuals Although AIT has 
proven efficacy in large, robust clinical trials in pri-
marily polysensitized patients [55, 69], more work is 
required to determine whether single-allergen source 
and multi-allergen source AIT also produce distinct 
immune and clinical responses in monosensitized 
and polysensitized patients [118]. The currently 
available literature suggests that when the clinically 
relevant allergen has been identified, AIT is effective 
also in polysensitized patients [118].
 13. Ideal schedule for sublingual AIT For some allergen 
extract preparations, efficacy (SLIT with pollen) has 
been shown with a pre-coseasonal administration 
schedule, as opposed to other extracts for which 
the year-round perennial schedule is recommended. 
This has implications for the cost-benefit analysis as 
well as for adherence. Until direct comparative stud-
ies between dosing are conducted, it is speculative 
as to which schedule adherence might ultimately be 
enhanced.
 14. Duration of AIT International harmonisation on the 
criteria used to determine the duration of AIT is 
necessary. Adherence to treatment, route of admin-
istration, cost, allergen source, patient’s comorbidi-
ties and polysensitisation are all factors that should 
be considered as well as the age of onset of AIT. It is 
usually recommended to perform AIT for a duration 
of 3 years, but data are insufficient.
 15. Cost-effectiveness A health technology assessment 
study funded by the UK National Institute for Health 
Research Health Technology Assessment (NIHR 
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HTA) programme concluded that a benefit from 
both SCIT and SLIT compared with placebo has 
been consistently demonstrated. However, the extent 
of this effectiveness in terms of clinical benefit is 
unclear. Both SCIT and SLIT may be cost-effective 
compared with AIT from around 6 years (threshold 
of £20,000–30,000 per QALY) [80]. In a US study 
based on Florida Medicaid data on allergic rhinitis 
patients from poverty environments, the cut-even 
point for SCIT was already reached at 3  months 
[119]. The results of this study are restricted to 
the US model and the population treated. Further 
research is urgently needed to establish the compara-
tive effectiveness of SCIT compared with SLIT and 
to provide more robust cost-effectiveness estimates 
[71, 80]. Although it is not accepted by regulators 
yet, cost-effectiveness might be best shown in more 
real-life trial designs.
 16. Novel forms of AIT Recombinant allergens [74, 120, 
121] or the chemical and molecular modification of 
allergens and the use of different routes of adminis-
tration of AIT should aim to facilitate its use for a 
wider scope of allergic diseases. However, these new 
options should be assessed in the context of the 
patient’s convenience and adherence to treatment, 
long-term efficacy, disease-modifying effects and 
cost-benefits. Biologics added to AIT may be effec-
tive for some (anti-IgE [122–124]) but not all targets 
(anti-IL-4 [125]). In this case, an economic evalua-
tion is needed to stratify the patients.
Proposal to integrate AIT in AIRWAYS ICPs
Strategic framework
Integration and dissemination of international and 
national clinical practice guidelines are part of the process 
of ICPs. ICPs differ from practice guidelines as they are 
utilized by a multidisciplinary team and focus on the qual-
ity and coordination of care. Clinicians are free to exercise 
their own professional judgment as appropriate. An ICP 
is intended to act as a guide to treatment for the single 
patient. Any alteration to the practice identified within 
the ICP algorithm should be noted as a variance. Vari-
ance analysis can be used to amend the ICP itself if, for a 
group of patients, the practice consistently differs from the 
pathway.
ICPs form all or part of the clinical record, docu-
ment the care given, and facilitate the evaluation of out-
comes for continuous quality improvement. They should 
empower patients and their health and social care givers.
Objectives
The aims of AIRWAYS ICPs are to:
  • Better understand the role of AIT across the life 
cycle, particularly in preschool children (prevention 
and treatment) and in the elderly.
  • Increase the awareness of the impact of AIT across 
the life cycle to promote AHA.
  • Better stratify patients who benefit the most from 
AIT in all age groups.
  • Launch a collaboration to develop care pathways for 
chronic respiratory allergic diseases integrating AIT 
in European countries and regions in the frame of 
AIRWAYS ICPs.
  • Follow and implement actions and plans suggested 
by this integrated collaboration.
  • Provide evidence for regulatory decisions.
  • Propose new policies in the EU. AIRWAYS ICPs and 
AIT to be incorporated in Action Plan B3 of the EIP 
on AHA.
  • Follow and implement actions and plans suggested 
by this integrated collaboration, which are to be 
endorsed by national health authorities.
Approach
This project aims to synergize current initiatives in AIT, 
allergic diseases and healthy ageing, as part of the AIR-
WAYS ICPs programme.
A multi-sectoral approach is proposed. It will include 
all targeted groups such as (1) the general popula-
tion (patients, parents, teachers, media, patient’s asso-
ciations), (2) primary care (general practitioners and 
general pediatricians, pharmacists, nurses) and (3) sec-
ondary care (allergists, organ and other allergy specialists 
including pediatrics, ENT, internal medicine, derma-
tology, respiratory, clinical immunologists, and patient 
associations).
Partners will include (1) relevant academic consortia 
(MeDALL, GA2LEN, ARIA, PRACTALL), (2) relevant 
academic societies (both national and international), 
(3) manufacturers of allergy diagnostics and allergen 
preparations.
A stratification of patients across the life cycle using 
novel biomarkers, e-health and CDSS.
The integration of modern e-health tools should be 
promoted. Indeed, the use of electronic information and 
communications technologies in health is rising rapidly 
in the developing world, offering essential improvements 
in the management of respiratory allergies. This tech-
nology will allow better disease control and monitoring, 
promoting AIT compliance. These will include: (1) the 
Sentinel Network of GA2LEN and MACVIA-LR, (2) the 
MASK model of MACVIA-LR, including novel CDSS [7, 
126] and (3) the currently available applications of certain 
investigators and pharmaceutical companies.
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A stepwise framework is favoured. The AIRWAYS ICPs 
group will collect data, make proposals and then dissemi-
nate and evaluate actions.
Step 1—Data collection We are aiming to create a port-
folio providing all available current published data on 
the subject. As an example, the most recent documents 
provided by EAACI (AIT guidelines and consensus 
reports), ARIA (rhinitis and asthma guidelines), and 
WAO (SLIT guidelines) will be included and deposited 
in the EIP on AHA repository.
Step 2—Proposals and actions We will summarize and 
select the best feasible proposals to integrate AIT in 
AIRWAYS ICP across the EU. As an example, the best 
windows of intervention for AIT in children and all 
possible interventions later in life will be scrutinized.
Step 3—Dissemination and follow-up Use of the pro-
posals will be promoted as much as possible and sur-
veyed. As an example, a module will be created for 
presentations at national and EU meetings, as well as 
for e-learning.
Step 4—Changes in policies Policies for senior citizens 
in countries should reflect the epidemiologic wave of 
the still unrecognized allergic diseases in the elderly. 
Novel approaches in health systems and reimburse-
ment policies are needed for AIT in well-stratified 
patients using modern technologies. The effectiveness, 
cost-effectiveness and safety of such policies will need 
to be established.
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